Harpeth Capital is pleased to announce that it served as financial advisor to IncellDx, Inc., a privately-held molecular diagnostics startup company dedicated to the detection of life threatening viral diseases, in connection with an investment in the Company by Bio-Reference Laboratories, Inc. (NASD:BRLI).

Founded in 2009 and based in Menlo Park, California, the Company's innovative technology currently targets the risk of developing cervical cancer, which is applicable to the large cervical cancer screening market. Cervical cancer is a leading cause of female mortality from cancer worldwide. IncellDx's reagents are being used today by a number of reference laboratories.